Virtual Roundtable
Improving the Co-management of Moderate to Severe Pediatric and Adult Atopic Dermatitis in Primary Care and Specialty Settings
Release Date: June 10, 2022
Expiration Date: June 9, 2023
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
Program Overview
Program Description
Atopic dermatitis (AD) is a chronic inflammatory disorder affecting millions of pediatric patients and, oftentimes, continuing into adulthood. When left untreated, moderate to severe AD is associated with significant morbidity and a wide range of comorbid conditions. In recent years, new and emerging therapies have greatly expanded therapeutic options available to healthcare professionals. Tune in to this dynamic roundtable webcast as specialist and primary care clinicians discuss strategies to improve care coordination and co-management of AD to optimize patient and disease outcomes.
Format
Video Roundtable
Learning Objectives
After completing this activity, participants should be better able to:
- Apply treatment options based on the stepwise management approach for AD in pediatric and adult patients
- Incorporate a co-management approach with shared decision-making into patient and caregiver encounters
- Select appropriate therapies for pediatric and adult patients with moderate to severe AD based on patient- and disease-related factors and the efficacy and safety of available therapies
Target Audience
Dermatology, primary care, and pediatric NPs and PAs
Faculty
Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN
- Director
- Lahey Dermatology Nurse Practitioner Training Program
- Lahey Hospital and Medical Center
- Burlington, Massachusetts
Tracey M. Piparo, PA-C
- Physician Assistant
- Division of Palliative Medicine
- RWJ Barnabas Health
- New Brunswick, New Jersey
- Immediate Past President
- New Jersey State Society of Physician Assistants
- Allentown, New Jersey
Jonathan I. Silverberg, MD, PhD, MPH
- Associate Professor
- Director of Clinical Research
- Director of Patch Testing
- George Washington University School of Medicine and Health Sciences
- Washington, DC
Details
NAPNAP CE Contact Hours Designation
This program is accredited for 1.0 NAPNAP CE contact hours of which 1.0 contain pharmacology (Rx) content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until June 9, 2023. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN: consulting fees: Sanofi-Genzyme.
Tracey M. Piparo, PA-C, has no relevant financial relationships to report.
Jonathan I. Silverberg, MD, PhD, MPH: consulting fees: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Sidekick Health; fees for non-CME/CE services: AbbVie, Eli Lilly, Leo, Pfizer, Regeneron, Sanofi; funds for research support (paid to institution): Galderma, Pfizer.
None of the members of the Planning Committee, NAPNAP staff, or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: June 10, 2022
Expiration date: June 9, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. PRP4891